ArticleBiopolymers2026
Prolonged Release of IL-10 From Enzyme-Mediated Poly-l-(Tyrosine-co-Phenylalanine) Nanocrystals Enhances Stability and Modulates Inflammatory Responses.
Article in Biopolymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
Protease-catalyzed synthesis of a peptide composed of l-tyrosine and l-phenylalanine (2.2:1 M ratio) was achieved in a natural deep eutectic solvent (NADES) medium and subsequently employed to encapsulate the anti-inflammatory cytokine interleukin-10 (IL-10). IL-10 was loaded into enzyme-mediated peptide nanocrystals at doses of 200 and 400 ng, achieving stable nanocomposite formulations. Release studies were conducted in phosphate-buffered saline (PBS, pH 7.4) at 37°C under gentle agitation, revealing a sustained release profile extending up to 30-31 days, with an initial release of approximately 16% within the first 5 days and near-complete release between Days 10 and 25, depending on loading. Encapsulation effectively protected IL-10 from rapid degradation observed for the free cytokine under identical conditions, resulting in markedly enhanced stability. The nanocrystals were further integrated into porcine gelatin-hyaluronic acid (Ge:HA) and microbial poly(hydroxybutyrate-co-valerate) (PHBV) matrices, where IL-10 release was further modulated, reaching up to ~80% release from Ge:HA and ~100% from PHBV-based systems over 31 days. Cytotoxicity assays using primary human dermal fibroblasts confirmed excellent biocompatibility of all formulations. Moreover, studies in PMA-activated THP-1 macrophage-like cells demonstrated reduced intracellular reactive oxygen species (ROS) and suppression of the pro-inflammatory cytokine IL-6, highlighting the combined protective and immunomodulatory effects of IL-10 encapsulation. The presence of tyrosine residues within the nanocarrier further suggests intrinsic antioxidant contributions. Overall, these results support enzyme-mediated peptide nanocrystals as an effective platform for the stabilization and prolonged release of IL-10, with strong potential for treating inflammation-related skin conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.